Efficacy and long‐term patency of fenestrated amplatzer devices in children

Lammers, Astrid E.; Derrick, Graham; Haworth, Sheila G.; Bonhoeffer, Philipp; Yates, Robert

doi:10.1002/ccd.21216

Cited by 38 publications

(29 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subsequently, small case series of patients with PH have demonstrated improved hemodynamic parameters and clinical benefit after atrial septostomy [7,9,[20][21][22][23][24][25].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A modified technique of stent fenestration of the interatrial septum improves patients with pulmonary hypertension

Troost

Delcroix

Gewillig

et al. 2008

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…Subsequently, small case series of patients with PH have demonstrated improved hemodynamic parameters and clinical benefit after atrial septostomy [7,9,[20][21][22][23][24][25].…”

Section: Discussionmentioning

confidence: 99%

“…A fenestrated device is likely to ensure better patency of an interatrial communication for a longer period. Yet in a recent series of children, a still high reocclusion rate has been reported using fenestrated Amplatzer devices (AGA Medical Corporation, Plymouth, MN) [20].…”

Section: Introductionmentioning

confidence: 99%

A modified technique of stent fenestration of the interatrial septum improves patients with pulmonary hypertension

Troost

Delcroix

Gewillig

et al. 2008

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…This approach has been followed by other investigators [22][23][24][25][26][27]. Both a high long-term occlusion rate [25] and long-term patency of these devices has been reported [26,27]. At present, it is difficult to anticipate the long-term risk/benefit of this approach.…”

Section: Discussionmentioning

confidence: 99%

Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension

Sandoval¹,

Gaspar²,

Peña³

et al. 2011

Eur Respir J

121

100

View full text Add to dashboard Cite

Atrial septostomy (AS) is a palliative treatment for right ventricular failure from severe pulmonary arterial hypertension (PAH). We sought to investigate the effect of AS, alone or combined with PAH-specific pharmacotherapy, on the survival of patients with PAH.We performed a retrospective analysis of the functional and haemodynamic changes in patients with PAH following AS, and long-term survival characteristics for the whole group and separately for the subgroup who received post-procedural pharmacotherapy. 50 procedures performed in 34 patients (mean¡SD age 35¡10 yrs) resulted in haemodynamic and symptomatic improvement in most of the patients. Only one (2%) procedure-related death occurred. Due to spontaneous closure of the defect, AS was repeated in 10 patients. In 21 patients, AS was the only form of treatment, while 11 received additional pharmacotherapy after AS. During follow-up (58.5¡38 months), 21 patients died; median survival of the group was 60 months (95% CI 43-77 months). Median survival for patients on pharmacotherapy additional to AS was 83 months (95% CI 57-109 months), which was better than that for patients with AS alone (53 months, 95% CI 39-67 months) (log-rank 6.52; p50.010).In selected patients with PAH, AS is a safe and effective intervention that exerts a beneficial impact on long-term survival. Survival appears to be improved when AS is combined with PAHspecific pharmacotherapy.

show abstract

“…If Rp improves in response to long-term oral pulmonary vasodilator therapy, complete closure can be performed. [50][51][52] All the above management strategies depend on effective reduction of Rp by novel pulmonary vasodilator therapy. However, the long-term outcomes of these strategies are currently unknown.…”

Section: Novel Strategies For Patients With Chd and Pah That Is Thougmentioning

confidence: 99%

Can Pulmonary Vasodilator Therapy Expand the Operative Indications for Congenital Heart Disease?

Inai

2015

Int. Heart J.

View full text Add to dashboard Cite

SummaryThe operability of congenital heart disease with left to right shunt depends on the severity of the pulmonary vascular disease induced by the increased pulmonary blood flow. Although some recommendations exist regarding operative indications according to pathological, hemodynamic, and epidemiological factors, the evidence underlying these recommendations is not conclusive. Recently, oral pulmonary vasodilator therapy has been reported to improve outcomes in patients with idiopathic pulmonary arterial hypertension, and this therapy also appears to be effective in patients with congenital heart disease and pulmonary arterial hypertension, including those with postoperative pulmonary hypertension and Eisenmenger syndrome. It is expected that the availability of novel pulmonary vasodilator therapy will expand the operative indications in patients with congenital heart disease with left to right shunt, but there is currently insufficient evidence to definitively determine this. A multicenter double-blind study should be conducted to further examine this issue. (Int Heart J 2015; 56: S12-S16)

show abstract

Efficacy and long‐term patency of fenestrated amplatzer devices in children

Abstract: Implantation of fenestrated atrial devices is feasible and effective; but the occlusion rate is high. Further research on fenestrated atrial septal devices with better long-term patency, and effective antithrombotic drug treatment is necessary.

Cited by 38 publications

References 31 publications

A modified technique of stent fenestration of the interatrial septum improves patients with pulmonary hypertension

A modified technique of stent fenestration of the interatrial septum improves patients with pulmonary hypertension

Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension

Can Pulmonary Vasodilator Therapy Expand the Operative Indications for Congenital Heart Disease?

Contact Info

Product

Resources

About